CCL1-CCR8 antagonists (antibodies or small molecules)



Pharmaceuticals and Biotechnology

The Technology

One of the four CCR8 ligands, CCL1, produced by CCR8+CD4+FOXp3+ regulatory T cells (Treg) that are major drivers of immune regulation, potentiates their suppressive activity via induction of CCR8, FOXp3, CD39, Granzyme-B, and IL-10 in a positive feedback mechanism, making them master drivers of immune regulation. This suggests that blocking the CCR8-CCL1 interaction, alone or combined with other immune checkpoint inhibitors, including antibodies or small molecules, may be a promising approach to treat malignant diseases.


  • Specific targeting of an important immune regulation axis for cancer immunotherapy

Applications and Opportunities

  • Treating malignant diseases
arrow Business Development Contacts
Dr. Gal Gur
Director of Business Development, Life Sciences